TFX Teleflex Incorporated

Teleflex Incorporated is divesting its Acute Care, Interventional Urology, and OEM businesses for a combined $2 billion in cash to streamline operations and focus on vascular access, interventional, and surgical segments. Intersurgical will acquire the Acute Care and Interventional Urology units for $530 million, while Montagu and Kohlberg will purchase the OEM business for $1.5 billion. Teleflex plans to use the majority of the $1.8 billion net proceeds to return capital to shareholders and reduce debt.

Wedge Capital Management L L P NC initiated a new position in Teleflex Incorporated (NYSE:TFX) by purchasing 220,082 shares valued at approximately $26.93 million. This comes as Teleflex reported strong quarterly earnings, beating EPS estimates and achieving a 19.4% year-over-year revenue increase. Despite the positive earnings and institutional ownership of 95.62%, analyst ratings are largely mixed, with a consensus price target of $142.43 against a current trading price near $121.73.

Teleflex Inc. stock underperformed on Friday compared to its competitors. The article mentions Unity Software's fourth-quarter financial results, irrelevant to Teleflex's performance, indicating a likely content aggregation error. The core assertion is Teleflex's underperformance, not Unity's earnings.

Truist Securities has increased its price target for Teleflex (TFX) shares to $135, up from $120, while maintaining a Hold rating on the stock. This adjustment comes after other analysts also recently updated their targets for the medical technology company. The article notes several other recent analyst actions and company news, including Teleflex's plans to divest three businesses for $2.03 billion.

Intersurgical has agreed to acquire the Acute Care and Interventional Urology businesses from Teleflex for $530 million. This acquisition aims to expand Intersurgical's product portfolio and operational capacity, creating a broader suite of solutions for customers worldwide. The transaction is expected to be completed in the second half of 2026, subject to regulatory approvals.

Zacks Research has adjusted its Q3 2026 EPS estimate for Teleflex (NYSE:TFX) to $3.88, down from $3.90, while maintaining a "Hold" rating. The medical technology company's last reported Q3 earnings on November 6th showed an EPS of $3.67, surpassing the consensus of $3.38, and revenue of $892.9 million, an increase of 19.4% year-over-year. Teleflex has also set its FY2025 EPS guidance between $14.00 and $14.20.